The companies focus to expand the use of AI for the development of therapies through translational research, clinical trials & diagnostic across the areas of oncology, fibrosis, and immunology
The companies also use AI pathology models to advance patient segmentation in clinical trials across multiple disease indications & will also develop AI-powered diagnostics measuring CD8 T-cell infiltration across oncology disease areas
The extended collaboration was based on the 2016 collaboration & has recently presented the results in the Journal of Modern Pathology that compares the use of AI-powered algorithms against manual IHC scoring PD-L1 expression related to outcomes across multiple cancer types in multiple trials
Ref: Businesswire | Image: BMS
